CYP2C19 genotype status and cure rates for H-pylori infection with rabeprazole plus amoxicillin.

被引：0
|
作者：
Ohashi, K
Furuta, T
Shirai, N
Kosuge, K
Watanabe, H
Ishizaki, T
机构：
[1] Kumamoto Univ, Dept Pharmacol Ther, Kumamoto, Japan
[2] Hamamatsu Univ Sch Med, Dept Internal Med 1, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Clin Pharmacol, Hamamatsu, Shizuoka, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OIIA1
引用
收藏
页码：140 / 140
页数：1
相关论文
共 50 条
  • [1] Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Nakagawa, K
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    PHARMACOGENETICS, 2001, 11 (04): : 341 - 348
  • [2] Individualized treatment strategy for the cure of H-pylori infection based on the susceptibility of H-pylori to antibiotics and the Cyp2C19 genotype status of the patients
    Furuta, T
    Kodaira, M
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Ohashi, K
    Hishida, A
    GASTROENTEROLOGY, 2005, 128 (04) : A426 - A426
  • [3] Cytochrome P4502C19 (CYP2C19) genotype status is not associated with cure rates of dual therapy with rabeprazole and amoxicillin for Helicobacter pylori.
    Uchihara, M
    Izumi, N
    Noguchi, O
    Asahina, Y
    Kanazawa, N
    Itakura, J
    Sakurai, K
    Tsuchiya, K
    Miyake, S
    Sakai, T
    GASTROENTEROLOGY, 2001, 120 (05) : A587 - A587
  • [4] The effect of genetic differences in CYP2C19 on cure rates for Helicobacter pylori by dual therapy with rabeprazole and amoxicillin
    Furuta, T
    Ohashi, K
    Takashima, M
    Shirai, N
    Kosuge, K
    Ishizaki, T
    Kaneko, E
    GASTROENTEROLOGY, 1999, 116 (04) : A167 - A167
  • [5] Effects of genetic differences in CYP2C19 status on cure rates of Helicobacter pylori infection by dual rabeprazole/amoxicillin therapy in comparison with dual omeprazole/amoxicillin therapy.
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Ohashi, K
    Ishizaki, T
    GASTROENTEROLOGY, 2000, 118 (04) : A495 - A495
  • [6] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin, and clarithromycin.
    Dojo, M
    Azuma, T
    Ohtani, M
    Muramatsu, A
    Suto, H
    Ito, Y
    Kuriyama, M
    GASTROENTEROLOGY, 2001, 120 (05) : A582 - A582
  • [7] Individualized treatment strategy for the cure of h. pylori infection based on the susceptibility of H. pylori to antibiotics and the Cyp2c19 genotype status of the patients
    Furuta, T
    Shirai, N
    Sugimoto, M
    Kajimura, M
    Ohashi, K
    Ishizaki, T
    GASTROENTEROLOGY, 2004, 126 (04) : A188 - A188
  • [8] CYP2C19 genotype and the PPIs - focus on rabeprazole
    Lim, PWY
    Goh, KL
    Wong, BCY
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S22 - S28
  • [9] The influence of the Cyp2c19*17 allele on the eradication rates of H-pylori by a triple therapy with lamsoprazole, clarithromycin and amoxicillin in Japan
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Kodaira, Chise
    Nishino, Masafumi
    Shirai, Naohito
    Ikuma, Mutsuhiro
    Hishida, Akira
    GASTROENTEROLOGY, 2007, 132 (04) : A612 - A612
  • [10] Individual metabolism of omeprazole is determined by the genotype of the enzyme CYP2C19 without relation to H-pylori infection.
    Sagar, M
    Bertilsson, L
    Dahl, ML
    Tybring, G
    Seensalu, R
    GASTROENTEROLOGY, 1997, 112 (04) : A275 - A275
12345